Mano Iyer’s unorthodox path to Medtech leadership led him to Europe where he co-founded a company, joined top VC firm Sofinnova, and founded ReCor Medical to test the use of renal denervation to treat hypertension. A tumultuous decade later, the company is now part of a new player in Medtech – Otsuka. What does this mean for ReCor, Iyer, and Otsuka?
Mano Iyer joined Sofinnova in 2008. Mano has spent the last 18 years working in the Medical Device Industry in various engineering, operational, and investment roles in the US, the Czech Republic, Germany, France, Switzerland, and the Netherlands, for public and private enterprises.
While at Sofinnova, Mano has been actively involved in numerous investments including CoAxia, ReCor Medical, and MD Start, the medical device incubator initiated by Sofinnova. Mano is a co-founder and CEO of ReCor Medical, a company focused on an intravascular ultrasound approach to renal denervation therapy.
Mano has a BS in Mechanical Engineering from the Rochester Institute of Technology and an MBA from the Stanford Graduate School of Business.
Meet Our Host
A follower and fan of medtech for nearly two decades, Tom Salemi is the former bureau chief, venture capital, at Elsevier Business Intelligence, where he oversaw coverage of venture investments in medtech.